Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma

PURPOSE: The multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of advanced-stage renal cell carcinoma. However, the safety and efficacy of this agent have yet to be evaluated in the preoperative period, where there may be potential advantages including tumor downstaging. Th...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Clin Oncol
मुख्य लेखकों: Cowey, C. Lance, Amin, Chirag, Pruthi, Raj S., Wallen, Eric M., Nielsen, Matthew E., Grigson, Gayle, Watkins, Cathy, Nance, Keith V., Crane, Jeffrey, Jalkut, Mark, Moore, Dominic T., Kim, William Y., Godley, Paul A., Whang, Young E., Fielding, Julia R., Rathmell, W. Kimryn
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Clinical Oncology 2010
विषय:
ORIGINAL REPORTS
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4525128/
https://ncbi.nlm.nih.gov/pubmed/20159822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.24.7759
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन